Faeth Therapeutics FTH 深 沪
等待开盘 10-23 09:30:00 美东时间
20.10
-0.470
-2.28%
华盛通- 最 高21.65
- 今 开20.40
- 成交量 31.45万股
- 最 低 20.00
- 昨 收 20.57
- 总市值 5.19亿
- 52周最高 42.1431
- 市盈率 静 --
- 换手率 1.22%
- 52周最低 7.45
- 委 比 -32.79%
- 总股本 2584.04万
- 历史最高 530.00
- 量 比 0.73
- 振 幅 8.02%
- 历史最低 5.00
- 每 手 1
- 风险率 9.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating.
10-16 22:31
Small-cap stocks with strong momentum grades and triple-digit YTD gains
A group of U.S. small-cap stocks is flashing A+ momentum grades in the latest quantitative screen, with several names posting triple-digit gains year to date. Seeking Alpha's Quant Momentum Grade meas...
09-17 21:55
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
美股牛股 | Commerce劲升18%，宣布5000万美元股票回购计划；Wealthfront升逾15%，Clover Health升逾8%
Commerce劲升18%，宣布5000万美元股票回购计划；Wealthfront升逾15%，Q2营收超预期，平台资产突破千亿大关；Clover Health升逾8%，德银首予“买入”评级>>
09-11 19:01
TD Cowen Initiates Coverage On Faeth Therapeutics with Buy Rating
TD Cowen analyst Tara Bancroft initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating.
09-09 22:30
美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer
— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration — Faeth expects topline data from its ongoing Phase 2 trial in s...
08-17 19:33
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Faeth Therapeutics To Present Translational Data And Pharmacokinetic/Pharmacodynamic Analysis For PIKTOR, Oral Combination Of Serabelisib And Sapanisertib, At 2026 Summit For STOP Cancer
— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8 — These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) Faeth Therap...
08-07 19:35
